In late 2020, after circulating for almost a year in the human population, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …

The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

Background The safety and immunogenicity of the bivalent omicron-containing mRNA-
1273.214 booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …

Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …

SARS-CoV-2 viral load and detection of infectious virus in the respiratory tract are the two
key parameters for estimating infectiousness. As shedding of infectious virus is required for …

Abstract In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified,
and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that …

The continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron
subvariants, including BQ. 1, BQ. 1.1, BA. 4.6, BF. 7, and BA. 2.75. 2. Here, we examine the …